Event
SynBioBeta 2025
May 5 - May 8
The Global Synthetic Biology Conference is an innovation network that brings together individuals who share a passion for biological engineering and sustainability.
Cambridge Consultants will be at Capgemini booth #316 during the event to meet with clients and discuss new advancements in biotech. Please stop by if you are attending the show.
Join Simon Karger on a panel discussion during breakout on how AI is rapidly progressing on protein engineering and where we are heading to in the near future.
Assessing Progress in AI for Protein Engineering: Where Are We Now, and Where Are We Going?
May 6, 2025 – 3:30 – 4:15 pm
Protein engineering is the most active frontier for AI in biotech. We are seeing the emergence of models that can make “zero shot” predictions of antibodies, and new variants of enzymes that would take millions of years for Evolution to produce. How should we be evaluating these models and their designs? What can we expect from the field of AI protein design moving forward?
Join Cassandra Padbury, Associate Director at Cambridge Consultants, part of Capgemini, on a panel discussion that will focus on tangible actions to accelerate this transition and realize the full economic promise of the bioeconomy.
Making It Happen: Accelerating the Global Bioeconomy
May 7, 2025 – 4:30 – 5:15 pm
This panel will bring together leaders across industry, public sector and the community to examine the systemic barriers slowing the bioeconomy’s growth and ask, “What best practices are we seeing to unlock progress?” Despite breakthroughs in synbio—including recent our findings showing 96% of businesses are advancing biosolutions—progress remains stalled by discovery costs, scaling challenges, regulatory uncertainty, and investment bottlenecks. Join this session to understand how these challenges are being overcome to ensure synbio moves from future predictions to large-scale impact.
For more information please visit: https://www.syntheticbiologysummit.com/event-speaker/david-willetts
Frances is a scientist and business leader focused on helping our clients to stand apart from their competition by harnessing the promise of Biotechnology innovation.
Ian is an experienced and innovative technical project leader with broad expertise and >20-year history of engineering biology using molecular, enzyme and microbial technology for the biomanufacture of pharmaceutical intermediates, industrial enzymes and therapeutic peptides.
Cassandra identifies opportunities and realises the value of ideas. With over 20 years in R&D and deep tech consulting, she delivers impact by foreseeing change and navigating emerging technology.
Helping our clients develop breakthrough medical devices. Simon helps to bring unparalleled technology, clinical insight and medical device development experience to developing advanced emerging medical technologies and therapies such as Synthetic Biology, Artificial Intelligence, Digital Health, Smart Implants and Cell & Gene Therapies.